Cited by 573Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Open access

Patel, Aniruddh P., Wang, Minxian, Pirruccello, James P., Ellinor, Patrick T., Ng, Kenney, Kathiresan, Sekar, Khera, Amit V.·2021·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/atvbaha.120.315291PMC PMC7769893

Open this paper in CoChat — free account Open PDF

Abstract

Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/atvbaha.120.315291

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citation
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383

Show all 50 references

Sorted by citations

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,284
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Lipoprotein(a) and its Significance in Cardiovascular Disease
Lau, F. D., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 377
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.03.001 · Cited by 360
2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 343
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 315
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease
Patel, A. P., Wang, M., Ruan, Y., Koyama, S., Clarke, S. L., Yang, X., Tcheandjieu, C., Agrawal, S., Fahed, A. C., Ellinor, P. T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02429-x · Cited by 309
Self-citation
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
Roeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene
Coassin, S., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.003 · Cited by 231
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
Nicholls, S. J., Nissen, S. E., Fleming, C., Urva, S., Suico, J. G., Berg, P. H., Linnebjerg, H., Ruotolo, G., Turner, P. K., & Michael, L. F. (2023) · JAMA · doi:10.1001/jama.2023.16503 · Cited by 217
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Yeang, C., Karwatowska‐Prokopczuk, E., Su, F., Dinh, B., Xia, S., Witztum, J. L., & Tsimikas, S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.032 · Cited by 222
Non-genetic influences on lipoprotein(a) concentrations
Enkhmaa, B., & Berglund, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.006 · Cited by 204
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Ni, W., Xi Zhong, S. H. E. N., Wang, Q., Návar, A. M., Nicholls, S. J., Wolski, K., Michael, L., Haupt, A., & Krege, J. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415818 · Cited by 183
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 190
Assessment of Cardiovascular Disease Risk
Goldsborough, E. F., Osuji, N., & Blaha, M. J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.005 · Cited by 169
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Tsimikas, S., & Marcovina, S. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.019 · Cited by 158
Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?
Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.008 · Cited by 156
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Nissen, S. E., Wolski, K., Cho, L., Nicholls, S. J., Kastelein, J. J. P., Leitersdorf, E., Landmesser, U., Blaha, M. J., Lincoff, A. M., Morishita, R., et al. (2022) · Open Heart · doi:10.1136/openhrt-2022-002060 · Cited by 148
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G. C., Mach, F., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.04.012 · Cited by 146
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
Kwan, T., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., DEEDWANIA, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 140
Lipoprotein(a) and ethnicities
Mehta, A., Jain, V., Saeed, A., Saseen, J. J., Gulati, M., Ballantyne, C. M., & Virani, S. S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.005 · Cited by 125
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease
Berman, A. N., Biery, D. W., Besser, S. A., Singh, A., Shiyovich, A., Weber, B., Huck, D. M., Divakaran, S., Hainer, J. M., Kaur, G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.031 · Cited by 124
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
Bhatia, H. S., Wandel, S., Willeit, P., Lesogor, A., Bailey, K., Ridker, P. M., Nestel, P. J., Simes, R. J., Tonkin, A. M., Schwartz, G. G., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069556 · Cited by 127
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D. C., Mauro, M. S., Raffo, C., Sangiorgio, G., Imbesi, A., Laudani, C., Mazzone, P. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.069210 · Cited by 126
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)
O’Donoghue, M. L., López, J. A. G., Knüsel, B., Gencer, B., Wang, H., Wu, Y., Kassahun, H., & Sabatine, M. S. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.004 · Cited by 112
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
Wong, N. D., Fan, W., Hu, X., Ballantyne, C. M., Hoogeveen, R. C., Tsai, M. Y., Browne, A., & Budoff, M. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.031 · Cited by 118
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 112
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
Trinder, M., Paruchuri, K., Haidermota, S., Bernardo, R. C., Zekavat, S. M., Gilliland, T., Januzzi, J. L., & Natarajan, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.055 · Cited by 106
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
Koschinsky, M. L., & Boffa, M. B. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.001 · Cited by 94
The Brussels International Declaration on Lipoprotein(a) Testing and Management
Kronenberg, F., Bedlington, N., Ademi, Z., Geantă, M., Silberzahn, T., Rijken, M., Kaal, A., Harada‐Shiba, M., Chen, Z., Thanassoulis, G., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119218 · Cited by 88
Lipoprotein(a): Knowns, unknowns and uncertainties
Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105812 · Cited by 84
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 84
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
Thomas, P. E., Vedel‐Krogh, S., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad055 · Cited by 82
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Hedegaard, B. S., Bork, C. S., Kaltoft, M., Klausen, I. C., Schmidt, E. B., Kamstrup, P. R., Langsted, A., & Nordestgaard, B. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.021 · Cited by 69
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Kronenberg, F., Mora, S., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000855 · Cited by 68
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
Volgman, A. S., Koschinsky, M. L., Mehta, A., & Rosenson, R. S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033654 · Cited by 68
Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies
Bhatia, H. S., & Wilkinson, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206040 · Cited by 67
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Tasdighi, E., Adhikari, R., Almaadawy, O., Leucker, T. M., & Blaha, M. J. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-100609 · Cited by 66
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity
Leistner, D. M., Laguna-Fernández, A., Haghikia, A., Abdelwahed, Y. S., Schatz, A.-S., Erbay, A., Roehle, R., Fonseca, A. F., Ferber, P. C., & Landmesser, U. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae007 · Cited by 60
Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies
Alhomoud, I. S., Talasaz, A. H., Mehta, A., Kelly, M. S., Sisson, E. M., Bucheit, J. D., Brown, R., & Dixon, D. L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2851 · Cited by 57
Finding very high lipoprotein(a): the need for routine assessment
Nurmohamed, N. S., Kaiser, Y., Schuitema, P. C. E., Ibrahim, S., Nierman, M. C., Fischer, J., Chamuleau, S. A. J., Knaapen, P., & Stroes, E. S. G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab167 · Cited by 56
Lipoprotein(a): from Causality to Treatment
Kronenberg, F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01187-6 · Cited by 55
Lipoprotein(a)
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 54
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
Clarke, R., Ende, A. V., Schmidt, L. E., Yin, X., Hill, M., Hughes, A. D., Pechlaner, R., Willeit, J., Kiechl, S. J., Watkins, H. C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321690 · Cited by 52
Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study
Strandkjær, N., Hansen, M. K., Nielsen, S. T., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Nordestgaard, B. G., Tabor, A., Bundgaard, H., Iversen, K. K., & Kamstrup, P. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab734 · Cited by 51
Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis
Xia, Q., Chen, Y., Yu, Z., Huang, Z., Yang, Y., Mao, A., & Qiu, W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1186330 · Cited by 50
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
MacDougall, D. E., Tybjærg‐Hansen, A., Knowles, J. W., Stern, T., Hartsuff, B., McGowan, M. P., Baum, S. J., Wilemon, K. A., & Nordestgaard, B. G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf297 · Cited by 49
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup, P. R., Neely, R. D. G., Nissen, S. E., Landmesser, U., Haghikia, A., Costa‐Scharplatz, M., Abbas, C. A., & Nordestgaard, B. G. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae032 · Cited by 48
Lipoprotein(a): Emerging insights and therapeutics
Kaur, G., Abdelrahman, K., Berman, A. N., Biery, D. W., Shiyovich, A., Huck, D. M., Garshick, M. S., Blankstein, R., & Weber, B. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100641 · Cited by 49
Discovery of potent small-molecule inhibitors of lipoprotein(a) formation
Diaz, N., Perez, C., Escribano, A., Sanz, G., Priego, J., Lafuente, C., Barberis, M., Calle, L. P., Espinosa, J. F., Priest, B. T., et al. (2024) · Nature · doi:10.1038/s41586-024-07387-z · Cited by 48
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease
Doherty, S., Hernandez, S., Rikhi, R. R., Mirzai, S., Reyes, C. D. L., McIntosh, S. W., Block, R., & Shapiro, M. D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00760-1 · Cited by 50
International Migration and Cardiovascular Health: Unraveling the Disease Burden Among Migrants to North America and Europe
Agyemang, C. O., van der Linden, E. L., Chilunga, F. P., & van den Born, B. H. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030228 · Cited by 50
Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification
Diederiks, N. M., van der Burgt, Y. E. M., Ruhaak, L. R., & Cobbaert, C. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2199353 · Cited by 45
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 50
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study
de Boer, L. M., Wiegman, A., Kroon, J., Tsimikas, S., Yeang, C., Peletier, M. C., Revers, A., Kastelein, J. J. P., Zwinderman, A. H., & Hutten, B. A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00156-0 · Cited by 43
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
Vavuranakis, M., Jones, S. R., Ziogos, E., Blaha, M. J., Williams, M. S., Foran, P., Schindler, T. H., Lai, S., Schulman, S. P., Gerstenblith, G., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.01.058 · Cited by 41
Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
Virani, S. S., Koschinsky, M. L., Maher, L. V., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.01.002 · Cited by 42
Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry
Satterfield, B. A., Dikilitas, O., Safarova, M. S., Clarke, S. L., Tcheandjieu, C., Zhu, X., Bastarache, L., Larson, E. B., Justice, A. E., Shang, N., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.120.003354 · Cited by 40
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank
Welsh, P. I., Zabiby, A. A., Byrne, H., Benbow, H. R., Itani, T., Farries, G., Costa‐Scharplatz, M., Ferber, P. C., Martin, L., Brown, R., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117437 · Cited by 39
Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults
Man, S., Zu, Y., Yang, X., Deng, Y., Shen, D., Ma, Y., Fu, J., Du, J., Yu, C., Lyu, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.032 · Cited by 39
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations
Ward, N. C., Watts, G. F., Bishop, W., Colquhoun, D., Hamilton-Craig, C. R., Hare, D. L., Kangaharan, N., Kostner, K., Kritharides, L., O’Brien, R. C., et al. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.11.015 · Cited by 37
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease
Barkas, F., Brandts, J., Bacquer, D. D., Jennings, C. S., Backer, G. D., Kotseva, K., Rydén, L., Lip, G. Y. H., Santos, R. D., Libby, P., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.010 · Cited by 38
Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
Maio, S. D., Lamina, C., Coassin, S., Forer, L., Würzner, R., Schönherr, S., & Kronenberg, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13338 · Cited by 37
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis
Qin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01215-5 · Cited by 36
Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population
Loh, W. J., Chang, X., Aw, T. C., Phua, S. K., Low, A. F.-H., Chan, M. Y., Watts, G. F., & Heng, C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.018 · Cited by 36
Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
Sohn, W. Y., Winkle, P. J., Neutel, J., Wu, Y., Jabari, F., Terrio, C., Varrieur, T., Wang, J., & Hellawell, J. L. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.07.008 · Cited by 36
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside—Part 1
Gallucci, G., Turazza, F. M., Inno, A., Canale, M. L., Silvestris, N., Farì, R., Navazio, A., Pinto, C., & Tarantini, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084232 · Cited by 37
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
Hardy, J., Niman, S., Goldfaden, R. F., Ashchi, M., Bisharat, M. B., Huston, J., Hartmann, H., & Choksi, R. R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00499-1 · Cited by 35
Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study
Deshotels, M. R., Sun, C., Nambi, V., Virani, S. S., Matsushita, K., Yu, B., Ballantyne, C. M., & Hoogeveen, R. C. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026762 · Cited by 36
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 36
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
Colantonio, L. D., Bittner, V., Safford, M. M., Marcovina, S. M., Brown, T. M., Jackson, E. A., Li, M., López, J. A. G., Monda, K. L., Plante, T. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025397 · Cited by 34
Understanding the ins and outs of lipoprotein (a) metabolism
Boffa, M. B., & Koschinsky, M. L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000823 · Cited by 34
Lipoprotein(a)—60 Years Later—What Do We Know?
Pasławska, A., & Tomasik, P. (2023) · Cells · doi:10.3390/cells12202472 · Cited by 31
Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals
Patel, D., Koschinsky, M. L., Agarwala, A., Natarajan, P., Bhatia, H. S., Mehta, A., Patel, J., Peters, M. G., Pandya, S., Sagheer, U., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040361 · Cited by 32
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Koschinsky, M. L., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.017 · Cited by 32
Concordance of a High Lipoprotein(a) Concentration Among Relatives
Reeskamp, L. F., Tromp, T. R., Patel, A. P., Ibrahim, S., Trinder, M., Haidermota, S., Hovingh, G. K., Stroes, E. S. G., Natarajan, P., & Khera, A. V. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3548 · Cited by 33
Self-citation
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN
Reijman, M. D., Kusters, D. M., Groothoff, J. W., Arbeiter, K., Dann, E. J., de Boer, L. M., de Ferranti, S. D., Gallo, A., Greber‐Platzer, S., Hartz, J. C., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117525 · Cited by 30
Lipoprotein(a) Is Associated With the Progression and Vulnerability of New-Onset Carotid Atherosclerotic Plaque
Duan, Y., Zhao, D. H., Sun, J., Liu, J., Wang, M., Hao, Y., Li, J., Liu, T., Xiao, L., Hao, Y., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.042323 · Cited by 29
Self-citation
Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care
Loh, W. J., Chan, D. C., Mata, P., & Watts, G. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905941 · Cited by 29
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Koutsogianni, A. D., Liamis, G. L., Liberopoulos, E. N., Adamidis, P. S., & Florentin, M. (2023) · Pharmaceuticals · doi:10.3390/ph16050750 · Cited by 29
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study
Bittner, V., Schwartz, G. G., Bhatt, D. L., Chua, T. S. J., Silva, H. A. D., Díaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., McGinniss, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.122 · Cited by 28
Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults
Kim, B. J., Lee, M. Y., Choi, H., Kwon, M., & Kang, J. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac271 · Cited by 27
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 26
Lipoprotein(a) and panvascular disease
Xu, R., Wang, Z., Dong, J., Yu, M., & Zhou, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02600-y · Cited by 29
Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry
Nakamura, H., Kataoka, Y., Nicholls, S. J., Puri, R., Kitahara, S., Murai, K., Sawada, K., Matama, H., Iwai, T., Honda, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.033 · Cited by 26

Authors: Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
Affiliations: Broad Institute (US)
IBM Research - Cambridge (United States) (US)
Corresponding author: Khera, Amit V.
ORCID: Patel, Aniruddh P.
Wang, Minxian
Pirruccello, James P.
Ellinor, Patrick T.
Ng, Kenney
Kathiresan, Sekar
Khera, Amit V.
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2021-01
Volume: 41
Issue: 1
Pages: 465-474
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/atvbaha.120.315291
PMC: PMC7769893
OpenAlex: W3097307979
Cited by: 567
References: 50
Citations by year: 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
FWCI: 39.95
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: American Heart Association (R01 HL128914, 18SFRN34110082)
Massachusetts General Hospital
Broad Institute
Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
Medical Research Council (MC_PC_17228)
National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
MeSH terms: Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks